Merck/Vioxx

After shares of pharmaceutical giant Merck & Co., Inc. lose tens of billions in market value in response to revelations surrounding the Company’s concealment of health risk associated with its blockbuster painkiller VIOXX, investors sue but the court dismisses the case on statute of limitations grounds. The case is appealed all the way to the United States Supreme Court. BLB&G’s efforts as Co-Lead Counsel for Merck shareholders are instrumental in securing a rare, unanimous Supreme Court decision clarifying the standard governing statute of limitations in securities fraud suits. The Supreme’s decision is a significant victory — not only for Merck investors but for all investors as it makes it more difficult for corporate wrongdoers to evade liability by concealing their fraud.